{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:22:09Z","timestamp":1792059729035,"version":"4.4.0"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.coph.2026.102626","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:32:52Z","timestamp":1774683172000},"page":"102626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Valproic acid: Mechanistic insights into neuronal actions, epigenetic modulation, and clinical risk"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3093-8572","authenticated-orcid":false,"given":"Ahmed M.","family":"Abd-Eldayem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2026.102626_bib1","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1134\/S0022093023050228","article-title":"Molecular mechanisms of valproic acid action on signalling systems and brain functions","volume":"59","author":"Tursunov","year":"2023","journal-title":"J Evol Biochem Physiol"},{"key":"10.1016\/j.coph.2026.102626_sref2","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.3390\/jcm14082673","article-title":"Repurposing antiepileptic drugs for cancer: a promising therapeutic strategy","volume":"14","author":"Tarawneh","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.coph.2026.102626_bib3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10822-020-00304-2","article-title":"Exploring the inhibitory activity of valproic acid against the HDAC family using an MMGBSA approach","volume":"34","author":"Sixto-L\u00f3pez","year":"2020","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.coph.2026.102626_bib4","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1017\/S1092852924002311","article-title":"Anatomical, behavioral, and cognitive teratogenicity associated with valproic acid: a systematic review","volume":"29","author":"Valentino","year":"2024","journal-title":"CNS Spectr"},{"key":"10.1016\/j.coph.2026.102626_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25010390","article-title":"Valproic acid in pregnancy revisited: neurobehavioral, biochemical and molecular changes affecting the embryo and fetus in humans and in animals: a narrative review","volume":"25","author":"Ornoy","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2026.102626_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/bdr2.2392","article-title":"Paternal valproate treatment and risk of childhood neurodevelopmental disorders: precautionary regulatory measures are insufficiently substantiated","volume":"116","author":"Garey","year":"2024","journal-title":"Birth Defects Res"},{"key":"10.1016\/j.coph.2026.102626_bib7","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-62059-2_37","article-title":"Mood stabilizers: pharmacology and biochemistry","author":"Hommers","year":"2022","journal-title":"NeuroPsychopharmacotherapy"},{"key":"10.1016\/j.coph.2026.102626_bib8","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharmacogenet Genom"},{"key":"10.1016\/j.coph.2026.102626_bib9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s40262-022-01171-w","article-title":"Clinical pharmacokinetic monitoring of free valproic acid levels: a systematic review","volume":"61","author":"Lin","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.coph.2026.102626_bib10","first-page":"81","volume":"10","author":"Walia","year":"2024"},{"key":"10.1016\/j.coph.2026.102626_sref11","doi-asserted-by":"crossref","first-page":"26549","DOI":"10.1073\/pnas.1909696116","article-title":"Valproic acid interactions with the NavMs voltage-gated sodium channel","volume":"116","author":"Zanatta","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2026.102626_bib12","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/bcp.12205","article-title":"Low threshold T-type calcium channels as targets for novel epilepsy treatments","volume":"77","author":"Powell","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.coph.2026.102626_sref13","doi-asserted-by":"crossref","DOI":"10.1186\/s13072-021-00432-5","article-title":"Changes in chromatin accessibility landscape and histone H3 core acetylation during valproic acid-induced differentiation of embryonic stem cells","volume":"14","author":"Baumann","year":"2021","journal-title":"Epigenetics Chromatin"},{"key":"10.1016\/j.coph.2026.102626_bib14","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bcpt.12201","article-title":"Induction of neurotrophic and differentiation factors in neural stem cells by valproic acid","volume":"115","author":"Almutawaa","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.coph.2026.102626_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2018.00117","article-title":"Valproic acid attenuates traumatic brain injury-induced inflammation in vivo: involvement of autophagy and the Nrf2\/ARE signaling pathway","volume":"11","author":"Chen","year":"2018","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.coph.2026.102626_sref16","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2026.102626_bib17","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10822-020-00304-2","article-title":"Exploring the inhibitory activity of valproic acid against the HDAC family using an MMGBSA approach","volume":"34","author":"Sixto-L\u00f3pez","year":"2020","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.coph.2026.102626_sref18","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41380-024-02732-0","article-title":"Valproic acid-induced teratogenicity is driven by senescence and prevented by Rapamycin in human spinal cord and animal models","volume":"30","author":"Pietrogrande","year":"2025","journal-title":"Mol Psychiatr"},{"key":"10.1016\/j.coph.2026.102626_bib19","first-page":"hzt003","article-title":"A scientific review: mechanisms of valproate-mediated teratogenesis","volume":"6","author":"Lloyd","year":"2013","journal-title":"Biosci Horizons Int J Student Res"},{"key":"10.1016\/j.coph.2026.102626_bib20","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1017\/S1092852924002311","article-title":"Anatomical, behavioral, and cognitive teratogenicity associated with valproic acid: a systematic review","volume":"29","author":"Valentino","year":"2024","journal-title":"CNS Spectr"},{"key":"10.1016\/j.coph.2026.102626_bib21","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1111\/epi.18392","article-title":"In vitro models of valproic acid to assess neurodevelopmental toxicity: a scoping review","volume":"66","author":"Sandvik","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.coph.2026.102626_bib22","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1159\/000485753","article-title":"Cellular effects of the antiepileptic drug valproic acid in glioblastoma","volume":"44","author":"Eckert","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.coph.2026.102626_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.33545\/27068919.2024.v6.i5a.1165","article-title":"The influence of different excipients on Valproic acid tablets in neurological disorder treatment","volume":"6","author":"Sharma","year":"2024","journal-title":"Int J Adv Acad Stud"},{"key":"10.1016\/j.coph.2026.102626_bib24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejphar.2014.01.020","article-title":"Valproic acid inhibits excess dopamine release in response to a fear-conditioned stimulus in the basolateral complex of the amygdala of methamphetamine-sensitized rats","volume":"730","author":"Miyagi","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2026.102626_sref25","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X17666181227165722","article-title":"Valproic acid and epilepsy: from molecular mechanisms to clinical evidences","volume":"17","author":"Romoli","year":"2018","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.coph.2026.102626_bib26","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1007\/s00213-023-06457-w","article-title":"Group I and group II metabotropic glutamate receptors are upregulated in the synapses of infant rats prenatally exposed to valproic acid","volume":"240","author":"D'Antoni","year":"2023","journal-title":"Psychopharmacol Ser"},{"key":"10.1016\/j.coph.2026.102626_bib27","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3390\/biom12111691","article-title":"The state of the dopaminergic and glutamatergic systems in the valproic acid mouse model of autism spectrum disorder","volume":"12","author":"Maisterrena","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.coph.2026.102626_bib28","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3892\/etm.2020.8802","article-title":"Effect of valproic acid on oxidative stress parameters of glutamate-induced excitotoxicity in SH-SY5Y cells","volume":"20","author":"Terzi\u0307o\u011flu Bebi\u0307to\u011flu","year":"2020","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.coph.2026.102626_bib29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3892\/ol.2024.14330","article-title":"Effect of valproic acid on histone deacetylase expression in oral cancer","volume":"27","author":"Al-Khafaji","year":"2024","journal-title":"Oncol Lett"},{"key":"10.1016\/j.coph.2026.102626_bib30","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3390\/genes9110522","article-title":"Valproic acid inhibits proliferation and reduces invasiveness in glioma stem cells through Wnt\/\u03b2 catenin signalling activation","volume":"9","author":"Riva","year":"2018","journal-title":"Genes"},{"key":"10.1016\/j.coph.2026.102626_bib31","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s12640-022-00622-3","article-title":"Valproic acid attenuated PTZ-Induced oxidative stress, inflammation, and apoptosis in the SH-SY5Y cells via modulating the TRPM2 channel","volume":"40","author":"Ahlatc\u0131","year":"2022","journal-title":"Neurotox Res"},{"key":"10.1016\/j.coph.2026.102626_bib32","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.4103\/NRR.NRR-D-23-01633","article-title":"Enhanced autophagic clearance of amyloid-\u03b2 via histone deacetylase 6-mediated V-ATPase assembly and lysosomal acidification protects against Alzheimer's disease in vitro and in vivo","volume":"20","author":"Long","year":"2025","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.coph.2026.102626_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/15593258241303646","article-title":"Valproic acid inhibits endoplasmic reticulum stress and reduces ferroptosis after traumatic brain injury","volume":"22","author":"Chen","year":"2024","journal-title":"Dose Response"},{"key":"10.1016\/j.coph.2026.102626_bib34","article-title":"Valproic acid protects primary dopamine neurons from MPP+-Induced neurotoxicity: Involvement of GSK3\u03b2 phosphorylation by Akt and ERK through the mitochondrial intrinsic apoptotic pathway","volume":"2017","author":"Zhang","year":"2017","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.coph.2026.102626_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/ijms23010023","article-title":"Neuroprotective effect of valproic acid on salicylate-induced tinnitus","volume":"23","author":"Song","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2026.102626_bib36","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1167\/iovs.09-3903","article-title":"Valproic acid\u2013mediated neuroprotection and regeneration in injured retinal ganglion cells","volume":"51","author":"Biermann","year":"2010","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2026.102626_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.903436","article-title":"Valproic acid reduces neuroinflammation to provide retinal ganglion cell neuroprotection in the retina axotomy model","volume":"10","author":"Tribble","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.coph.2026.102626_bib38","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1007\/s10753-017-0574-9","article-title":"Anti-inflammatory effects of valproic acid in a rat model of renal ischemia\/reperfusion injury: alteration in cytokine profile","volume":"40","author":"Amirzargar","year":"2017","journal-title":"Inflammation"},{"key":"10.1016\/j.coph.2026.102626_bib39","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/09731296241234976","article-title":"Research progress in regulatory mechanism of valproic acid on inflammatory responses to burns and trauma","volume":"20","author":"Zhu","year":"2024","journal-title":"Pharmacogn Mag"},{"key":"10.1016\/j.coph.2026.102626_bib40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/nop\/npac078","article-title":"Valproic acid as a radio-sensitizer in glioma: a systematic review and meta-analysis","volume":"10","author":"Sullivan","year":"2023","journal-title":"Neuro-Oncol Pract"},{"key":"10.1016\/j.coph.2026.102626_bib41","unstructured":"Valproic acid and valproate in alzheimer disease - clinical trials registry - ICH GCP. [date unknown]."},{"key":"10.1016\/j.coph.2026.102626_bib42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1192\/bja.2019.8","article-title":"Valproate in dementia: time to move on?: commentary on\u2026 cochrane corner","volume":"25","author":"Dhindsa","year":"2019","journal-title":"BJPsych Adv"},{"key":"10.1016\/j.coph.2026.102626_bib43","first-page":"1976","article-title":"Valproic acid regulates Ang II-induced pericyte-myofibroblast trans-differentiation via MAPK\/ERK pathway","volume":"10","author":"Zhang","year":"2018","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.coph.2026.102626_bib44","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fnagi.2019.00062","article-title":"Valproic acid stimulates hippocampal neurogenesis via activating the Wnt\/\u03b2-Catenin signaling pathway in the APP\/PS1\/Nestin-GFP triple transgenic mouse model of alzheimer's disease","volume":"11","author":"Zeng","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.coph.2026.102626_bib45","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.1007\/s12035-024-04003-z","article-title":"Therapeutic potential effect of Glycogen synthase Kinase 3 beta (GSK-3\u03b2) inhibitors in parkinson disease: exploring an overlooked avenue","volume":"61","author":"Turkistani","year":"2024","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.coph.2026.102626_bib46","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.neuropharm.2015.06.013","article-title":"An in vitro model for synaptic loss in neurodegenerative diseases suggests a neuroprotective role for valproic acid via inhibition of cPLA2 dependent signalling","volume":"101","author":"Williams","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.coph.2026.102626_bib47","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1038\/s41598-021-81794-4","article-title":"Valproic acid influences the expression of genes implicated with hyperglycaemia-induced complement and coagulation pathways","volume":"11","author":"Felisbino","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2026.102626_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2022.890221","article-title":"An individualized medication model of sodium valproate for patients with bipolar disorder based on machine learning and deep learning techniques","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2026.102626_sref49","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3390\/ijms26031082","article-title":"Pharmaco-Multiomics: a new frontier in precision psychiatry","volume":"26","author":"Dhieb","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2026.102626_bib50","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/cns.12445","article-title":"Valproic acid modifies synaptic structure and accelerates neurite outgrowth via the glycogen synthase Kinase-3\u03b2 signaling pathway in an alzheimer's disease model","volume":"21","author":"Long","year":"2015","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.coph.2026.102626_bib51","first-page":"103","article-title":"Valproic acid and\/or rapamycin preconditioning protects hair follicle stem cells from oxygen glucose serum deprivation-induced oxidative injury via activating Nrf2 pathway","volume":"13","author":"Keshavarzi","year":"2024","journal-title":"Mol Biol Res Commun"},{"key":"10.1016\/j.coph.2026.102626_bib52","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/iub.1445","article-title":"Valproic acid sensitizes human glioma cells to gefitinib-induced autophagy","volume":"67","author":"Chang","year":"2015","journal-title":"IUBMB Life"},{"key":"10.1016\/j.coph.2026.102626_bib53","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.4103\/1673-5374.193227","article-title":"Valproic acid as a microRNA modulator to promote neurite outgrowth","volume":"11","author":"Oikawa","year":"2016","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.coph.2026.102626_bib54","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s11940-024-00798-3","article-title":"The current role of valproic acid in the treatment of epilepsy: a glimpse into the present of an old ally","volume":"26","author":"Espinosa-Jovel","year":"2024","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.coph.2026.102626_bib55","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jpsychires.2021.11.021","article-title":"Long-term use of valproic acid reduced mortality in bipolar disorder patients in a Taiwanese population: an association analysis using the national health insurance research database (NHIRD)","volume":"149","author":"Hsieh","year":"2022","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.coph.2026.102626_bib56","article-title":"Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults","volume":"2013","author":"Linde","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coph.2026.102626_sref57","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103658","article-title":"Beyond epilepsy: the expanding role of valproic acid in Alzheimer disease therapy - a review","volume":"392","author":"Markowicz-Piasecka","year":"2025","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.coph.2026.102626_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-022-00785-3","article-title":"Monocarboxylate transporter functions and neuroprotective effects of valproic acid in experimental models of amyotrophic lateral sclerosis","volume":"29","author":"Gyawali","year":"2022","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.coph.2026.102626_bib59","doi-asserted-by":"crossref","first-page":"188","DOI":"10.34172\/biomedrb.2024.26","article-title":"A comprehensive insight into the role of valproic acid in neurodegenerative disorders: an updated review","volume":"2","author":"Razilou","year":"2024","journal-title":"Biomed Res Bull"},{"key":"10.1016\/j.coph.2026.102626_bib60","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4088\/JCP.08m04960yel","article-title":"A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania","volume":"71","author":"Hirschfeld","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.coph.2026.102626_bib61","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.2174\/138161207782360528","article-title":"Valproic acid as anti-cancer drug","volume":"13","author":"Michaelis","year":"2007","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.coph.2026.102626_bib62","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.3390\/cancers13143409","article-title":"Valproic acid and breast cancer: state of the art in 2021","volume":"13","author":"Wawruszak","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.coph.2026.102626_bib63","doi-asserted-by":"crossref","DOI":"10.1177\/09636897211027524","article-title":"Valproic acid suppresses breast cancer cell growth through triggering pyruvate kinase M2 isoform mediated warburg effect","volume":"30","author":"Li","year":"2021","journal-title":"Cell Transplant"},{"key":"10.1016\/j.coph.2026.102626_bib64","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1021\/jacsau.4c00991","article-title":"Epigenetic modifier drug valproic acid enhances cancer metaphase chromosome elasticity and electron transport: an atomic force microscopy approach","volume":"5","author":"Agrawal","year":"2025","journal-title":"JACS Au"},{"key":"10.1016\/j.coph.2026.102626_bib65","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/ijc.24158","article-title":"Valproic acid enhances bosutinib cytotoxicity in colon cancer cells","volume":"124","author":"Mologni","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coph.2026.102626_bib66","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920929589","article-title":"Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin\/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol","volume":"12","author":"Avallone","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.coph.2026.102626_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-025-07902-8","article-title":"Valproic acid improves the efficacy of oxaliplatin\/fluoropyrimidine-based chemotherapy by targeting cancer stem cell via \u03b2-Catenin modulation in colorectal cancer","volume":"16","author":"Roca","year":"2025","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.coph.2026.102626_bib68","doi-asserted-by":"crossref","first-page":"31","DOI":"10.18632\/oncotarget.430","article-title":"A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer","volume":"3","author":"Stauber","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.coph.2026.102626_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00732","article-title":"Valproic acid synergizes with Cisplatin and cetuximab in vitro and in vivo in head and neck cancer by targeting the mechanisms of resistance","volume":"8","author":"Iannelli","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.coph.2026.102626_bib70","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-020-01723-7","article-title":"Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition","volume":"39","author":"Iannelli","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.coph.2026.102626_bib71","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/abbs\/gmab002","article-title":"Inhibition of lipogenesis and induction of apoptosis by valproic acid in prostate cancer cells via the C\/EBP\u03b1\/SREBP-1 pathway","volume":"53","author":"Pang","year":"2021","journal-title":"Acta Biochim Biophys Sin"},{"key":"10.1016\/j.coph.2026.102626_bib72","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3390\/biomedicines10030517","article-title":"The class I HDAC inhibitor valproic acid strongly potentiates gemcitabine efficacy in pancreatic cancer by immune system activation","volume":"10","author":"Blaauboer","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.coph.2026.102626_bib73","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/jb\/mvn074","article-title":"Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo","volume":"144","author":"Sami","year":"2008","journal-title":"J Biochem"},{"key":"10.1016\/j.coph.2026.102626_bib74","doi-asserted-by":"crossref","DOI":"10.5812\/ijcm-120224","article-title":"Anti-proliferative and apoptotic effects of valproic acid on HeLa cells","volume":"15","author":"Hashemi","year":"2022","journal-title":"Int J Cancer Manag"},{"key":"10.1016\/j.coph.2026.102626_sref75","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s00044-023-03130-x","article-title":"A review of the mechanisms of valproate-induced liver injury with an emphasis on the role of reactive metabolites discovered by Tom Baillie","volume":"32","author":"Uetrecht","year":"2023","journal-title":"Med Chem Res"},{"key":"10.1016\/j.coph.2026.102626_sref76","article-title":"Transcription factor binding and individual genetic risk for valproate teratogenicity","author":"Anderson","year":"2025","journal-title":"medRxiv"},{"key":"10.1016\/j.coph.2026.102626_bib77","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/epi.16827","article-title":"Prenatal valproate exposure and adverse neurodevelopmental outcomes: does sex matter?","volume":"62","author":"Honybun","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.coph.2026.102626_bib78","series-title":"Valproic acid during pregnancy and after delivery : a narrative review","author":"Maristany","year":"2025"},{"key":"10.1016\/j.coph.2026.102626_bib79","doi-asserted-by":"crossref","first-page":"66","DOI":"10.33545\/pathol.2019.v2.i2b.79","article-title":"Hematological changes in adult patients on valproic acid therapy","volume":"2","author":"Hv","year":"2019","journal-title":"Int J Clin Diagnostic Pathol"},{"key":"10.1016\/j.coph.2026.102626_bib80","first-page":"39","article-title":"Hematological side effects of valproate used for the treatment of epilepsy","volume":"9","author":"Tedavisinde","year":"2021","journal-title":"Nam\u0131k Kemal Med J"},{"key":"10.1016\/j.coph.2026.102626_bib81","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2174\/1871527320666210811162345","article-title":"Hematological consequences of valproic acid in pediatric patients: a systematic review with a mechanistic approach","volume":"21","author":"Riahi-Zanjani","year":"2021","journal-title":"CNS Neurol Disord - Drug Targets"},{"key":"10.1016\/j.coph.2026.102626_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264351","article-title":"Assessment of need for hemostatic evaluation in patients taking valproic acid: a retrospective cross-sectional study","volume":"17","author":"Post","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2026.102626_bib83","first-page":"6044","volume":"12","author":"Bischof","year":"2023"},{"key":"10.1016\/j.coph.2026.102626_bib84","doi-asserted-by":"crossref","first-page":"2","DOI":"10.52768\/jjgastro\/1194","article-title":"Valproic acid-induced acute pancreatitis: first case report in Morocco and literature review","volume":"4","author":"Salahedddine","year":"2024","journal-title":"Japanese J Gastroenterol Res"},{"key":"10.1016\/j.coph.2026.102626_bib85","article-title":"Valproic acid-induced acute pancreatitis","volume":"61","author":"Jain","year":"2019","journal-title":"Indian J Psychiatry"},{"key":"10.1016\/j.coph.2026.102626_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13030-017-0101-0","article-title":"Association between the blood concentrations of ammonia and carnitine\/amino acid of schizophrenic patients treated with valproic acid","volume":"11","author":"Ando","year":"2017","journal-title":"Biopsychosoc Med"},{"key":"10.1016\/j.coph.2026.102626_bib87","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jhep.2010.11.031","article-title":"New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA","volume":"55","author":"Aires","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.coph.2026.102626_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107967","article-title":"Valproic acid-induced encephalopathy: a review of clinical features, risk factors, diagnosis, and treatment","volume":"120","author":"Wu","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.coph.2026.102626_bib89","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bcpt.13049","article-title":"Risk factors for valproic acid-induced hyperammonaemia in Chinese paediatric patients with epilepsy","volume":"123","author":"Zhu","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.coph.2026.102626_bib90","doi-asserted-by":"crossref","DOI":"10.1080\/17425255.2025.2510302","article-title":"Drug-drug interaction between anti-seizure medications in Dravet syndrome and Lennox-Gastaut syndrome","author":"Roberti","year":"2025","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.coph.2026.102626_bib91","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/0018578719831974","article-title":"Valproate interaction with carbapenems: review and recommendations","volume":"55","author":"Al-Quteimat","year":"2020","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.coph.2026.102626_bib92","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/00498254.2022.2117109","article-title":"The impact of ibuprofen on valproic acid plasma concentration in pediatric patients","volume":"52","author":"Gao","year":"2022","journal-title":"Xenobiotica"},{"key":"10.1016\/j.coph.2026.102626_bib93","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s40263-022-00955-9","article-title":"Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies","volume":"36","author":"Strzelczyk","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.coph.2026.102626_bib94","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.seizure.2019.04.003","article-title":"Risk of valproic acid-related alopecia: a systematic review and meta-analysis","volume":"69","author":"Wang","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.coph.2026.102626_bib95","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1007\/s10787-025-01695-0","article-title":"Modulation of the cognitive impairment associated with Alzheimer's disease by valproic acid: possible drug repurposing","volume":"33","author":"Sorial","year":"2025","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.coph.2026.102626_bib96","doi-asserted-by":"crossref","first-page":"6600","DOI":"10.3390\/ijms26146600","article-title":"Valproic acid reduces invasiveness and cellular growth in 2D and 3D glioblastoma cell lines","volume":"26","author":"Giordano","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2026.102626_bib97","doi-asserted-by":"crossref","DOI":"10.5772\/54824","article-title":"Valproic acid in autism spectrum disorder: from an environmental risk factor to a reliable animal model","author":"Gottfried","year":"2013","journal-title":"Recent Adv Autism Spectr Disord - Vol I"},{"key":"10.1016\/j.coph.2026.102626_bib98","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/jhg.2017.91","article-title":"The pharmacogenomics of valproic acid","volume":"62","author":"Zhu","year":"2017","journal-title":"J Hum Genet"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489226000226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489226000226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:10:23Z","timestamp":1780315823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489226000226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":98,"alternative-id":["S1471489226000226"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2026.102626","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valproic acid: Mechanistic insights into neuronal actions, epigenetic modulation, and clinical risk","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2026.102626","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102626"}}